UnitedHealthcare · Sotatercept · US health-plan appeal rights

Sotatercept denied as not medically necessary by UnitedHealthcare?

Q: How long do I have to appeal a UnitedHealthcare Sotatercept denial?

Internal appeal window: Typically 180 days from the denial date. External review window: Typically 60–120 days after the final internal denial. The clock starts from the date on the denial letter.

Most insurers reverse a medical-necessity denial when the appeal cites the specific clinical guideline (NCCN, ADA, AACE, etc.) that supports the requested treatment for your indication.

By Michael John Ryan, Founder & Privacy Officer, DenialHelp, LLC

Last reviewed 2026-05-09

Policy data current as of 2026-04-26

US health-plan appeal rights

Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules

Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.

Internal appeal window

Typically 180 days from the denial date

External review window

Typically 60–120 days after the final internal denial

What UnitedHealthcare typically requires

Diagnosis WHO Group 1 PAH confirmed by RHC (mPAP ≥20 mmHg, PCWP ≤15, PVR ≥2 WU). WHO FC II or III. On stable background PAH therapy ≥3 mo (commonly ERA + PDE5i ± prostacyclin). Prescribed by PH specialist at PHA-accredited center. Hgb monitoring per REMS. Reauth at 6 mo with 6MWD/FC/NT-proBNP/REVEAL improvement.

Source policy: OptumRx Winrevair (Sotatercept) Prior Authorization (Policy #2024D0099B)

What works in the appeal

Winrevair FDA-approved Mar 26, 2024 PAH FC II–III on background therapy — NOT investigational. STELLAR Hoeper NEJM 2023;388(16):1478-1490 — Phase 3 n=323, 6MWD +40.8 m vs placebo, NT-proBNP −229 pg/mL, PVR −165 dyn·s·cm⁻⁵, 84% of trial patients on background triple. ZENITH (high-risk FC III/IV) and HYPERION (newly diagnosed) extensions. ESC/ERS 2022 + 7th World Symposium 2024 endorse activin signaling pathway as fourth treatment pillar. First new PAH mechanism in 16 years.

Next steps

Find the date on the denial letter — your appeal window starts there.
Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
Request the insurer's claim file in writing — they must provide it.
Submit your appeal in writing with new clinical evidence and a physician statement.

Get the letter drafted

DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.

Start my appeal — $30 with code SEO25 →

Related appeal guides

Other UnitedHealthcare appeals

Other denial reasons for UnitedHealthcare Sotatercept

denied for failing step therapy denied as non-formulary denied for missing prior authorization denied as experimental or investigational denied as not FDA-approved for this use

This guide describes general US federal appeal rights based on Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules. Your specific plan documents (Summary of Benefits and Coverage, Evidence of Coverage) override anything here. DenialHelp is not your lawyer and not your physician — we draft appeal letters that your physician signs. Outcomes depend on your insurer's decision and factors outside our control. Reviewed by Michael John Ryan on 2026-05-09. Editorial standards: denialhelp.com/authors.